Myocardial No-Reflow in Humans
Key result
Personalized therapy targets myocardial no-reflow, which affects up to 50% of STEMI patients.
Why the study?
No-reflow after primary PCI in STEMI patients has a multifactorial pathogenesis and variable response to treatment, necessitating personalized management strategies.
Population
Patients presenting with STEMI undergoing primary PCI
Comparison
Various therapeutic strategies including thrombus aspiration versus standard procedure
Design
Review article
Authors
Discussion
Loading...
Member takes
Implication
This review proposes a personalized management approach for myocardial no-reflow in STEMI patients based on individual pathogenetic mechanisms.
Key Points
- To review the multifactorial pathogenesis and clinical predictors of myocardial no-reflow following primary percutaneous coronary intervention and propose a personalized management framework.
- Narrative synthesis of clinical evidence on the incidence (5% to 50%), mechanisms, biomarkers, and therapies for no-reflow in ST-segment elevation myocardial infarction.
- Evaluation of preventive and therapeutic strategies, specifically comparing mechanical thrombus aspiration prior to stent placement against standard percutaneous coronary intervention.
- Myocardial no-reflow occurs in 5% to 50% of patients with ST-segment elevation myocardial infarction despite successful epicardial coronary recanalization and correlates with worse clinical prognosis.
- Pathogenetic contributors include distal embolization, ischemia-reperfusion injury, and microvascular susceptibility; mechanical thrombus aspiration reduces embolization and improves perfusion compared with standard care.
- Because the predominant pathological driver varies across patients, no single mechanical or pharmacologic intervention uniformly succeeds, indicating the necessity of personalized mechanism-based therapies.
Structured PICO
P
Population
Patients presenting with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
I
Intervention
Personalized management of no-reflow based on the assessment of prevailing mechanisms, and various therapeutic strategies including thrombus aspiration
This review proposes a personalized management approach for myocardial no-reflow in STEMI patients based on individual pathogenetic mechanisms.
Cite This Study
Niccoli et al. (2009) conducted a review in ST-segment elevation myocardial infarction with no-reflow. Personalized management of no-reflow was evaluated. Myocardial no-reflow occurs in 5% to 50% of STEMI patients after primary PCI, prompting the proposal of a personalized management strategy based on individual pathogenetic mechanisms.